Posaconazole Is a Potent Inhibitor of Sterol 14α-Demethylation in Yeasts and Molds
Open Access
- 1 October 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (10) , 3690-3696
- https://doi.org/10.1128/aac.48.10.3690-3696.2004
Abstract
Posaconazole (POS; SCH 56592) is a novel triazole that is active against a wide variety of fungi, including fluconazole-resistant Candida albicans isolates and fungi that are inherently less susceptible to approved azoles, such as Candida glabrata. In this study, we compared the effects of POS, itraconazole (ITZ), fluconazole (FLZ), and voriconazole (VOR) on sterol biosynthesis in strains of C. albicans (both azole-sensitive and azole-resistant strains), C. glabrata, Aspergillus fumigatus, and Aspergillus flavus. Following exposure to azoles, nonsaponifiable sterols were extracted and resolved by liquid chromatography and sterol identity was confirmed by mass spectroscopy. Ergosterol was the major sterol in all but one of the strains; C. glabrata strain C110 synthesized an unusual sterol in place of ergosterol. Exposure to POS led to a decrease in the total sterol content of all the strains tested. The decrease was accompanied by the accumulation of 14α-methylated sterols, supporting the contention that POS inhibits the cytochrome P450 14α-demethylase enzyme. The degree of sterol inhibition was dependent on both dose and the susceptibility of the strain tested. POS retained activity against C. albicans isolates with mutated forms of the 14α-demethylase that rendered these strains resistant to FLZ, ITZ, and VOR. In addition, POS was a more potent inhibitor of sterol synthesis in A. fumigatus and A. flavus than either ITZ or VOR.Keywords
This publication has 19 references indexed in Scilit:
- Application of Real-Time Quantitative PCR to Molecular Analysis of Candida albicans Strains Exhibiting Reduced Susceptibility to AzolesAntimicrobial Agents and Chemotherapy, 2004
- Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilitiesThe Pediatric Infectious Disease Journal, 2003
- Histone Deacetylase Inhibitors Enhance Candida albicans Sensitivity to Azoles and Related Antifungals: Correlation with Reduction in CDR and ERG UpregulationAntimicrobial Agents and Chemotherapy, 2002
- Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000Antimicrobial Agents and Chemotherapy, 2002
- Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesisJournal of Mass Spectrometry, 2002
- In Vitro and In Vivo Effects of 14α-Demethylase ( ERG11 ) Depletion in Candida glabrataAntimicrobial Agents and Chemotherapy, 2001
- Aspergillosis Case-Fatality Rate: Systematic Review of the LiteratureClinical Infectious Diseases, 2001
- A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)Journal of Antimicrobial Chemotherapy, 2000
- Effects of voriconazole on Candida glabratain vitroJournal of Antimicrobial Chemotherapy, 1999
- Anti-CandidaDrugs — The Biochemical Basis for Their ActivityCRC Critical Reviews in Microbiology, 1987